Welcome to LookChem.com Sign In|Join Free

CAS

  • or

570396-89-3

Post Buying Request

570396-89-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

570396-89-3 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 570396-89-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,7,0,3,9 and 6 respectively; the second part has 2 digits, 8 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 570396-89:
(8*5)+(7*7)+(6*0)+(5*3)+(4*9)+(3*6)+(2*8)+(1*9)=183
183 % 10 = 3
So 570396-89-3 is a valid CAS Registry Number.

570396-89-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name 3-naphthalen-1-ylpyridine-4-carbonitrile

1.2 Other means of identification

Product number -
Other names -

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:570396-89-3 SDS

570396-89-3Relevant articles and documents

Aryl tetrahydropyridine inhibitors of farnesyltransferase: Glycine, phenylalanine and histidine derivatives

Gwaltney II, Stephen L.,O'Connor, Stephen J.,Nelson, Lissa T. J.,Sullivan, Gerard M.,Imade, Hovis,Wang, Weibo,Hasvold, Lisa,Li, Qun,Cohen, Jerome,Gu, Wen-Zhen,Tahir, Stephen K.,Bauch, Joy,Marsh, Kennan,Ng, Shi-Chung,Frost, David J.,Zhang, Haiying,Muchmore, Steve,Jakob, Clarissa G.,Stoll, Vincent,Hutchins, Charles,Rosenberg, Saul H.,Sham, Hing L.

, p. 1359 - 1362 (2007/10/03)

Inhibitors of farnesyltransferase are effective against a variety of tumors in mouse models of cancer. Clinical trials to evaluate these agents in humans are ongoing. In our effort to develop new farnesyltransferase inhibitors, we have discovered a series of aryl tetrahydropyridines that incorporate substituted glycine, phenylalanine and histidine residues. The design, synthesis, SAR and biological properties of these compounds will be discussed.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 570396-89-3